Skip to main
ABBV

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 30%
Buy 55%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie is a global biopharmaceutical company that specializes in discovering, developing, and commercializing advanced therapies in areas such as immunology, oncology, neuroscience, and aesthetics. The company's strong exposure to these key therapeutic areas, along with its recent acquisitions of Allergan, Cerevel, and ImmunoGen, have contributed to a diverse and robust portfolio of products and drugs. Additionally, AbbVie has shown a commitment to sustainability through its governance and focus on patient access, while also mitigating risks in areas such as pharmaceutical pricing pressures and supply chain vulnerabilities. Overall, these factors make AbbVie a strong and stable investment with potential for growth in the coming years.

Bears say

AbbVie is facing increasing competition in the immunology space, potential negative pipeline results, and legal risks from patent challenges. Despite its strong portfolio and potential for growth, the company's valuation is currently trading at a premium compared to its peers and may face pressures on its operating margins, resulting in a slower EPS growth and contraction in its P/E multiple. The addition of the Apogee pipeline and diversity initiatives show long-term sustainability efforts, but there are still looming risks and uncertainties in the company's future.

AbbVie (ABBV) has been analyzed by 20 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 55% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 20 analysts, AbbVie (ABBV) has a Buy consensus rating as of Aug 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $277.35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $277.35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.